Shares of Cempra, Inc. (NASDAQ:CEMP) have been given an average rating of “Hold” by the twenty research firms that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $8.70.
CEMP has been the topic of several recent research reports. Vetr raised Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 price objective on the stock in a report on Monday, May 1st. Zacks Investment Research raised Cempra from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $3.00 price objective on shares of Cempra in a report on Thursday, May 25th. Finally, ValuEngine cut Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
A number of hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in Cempra during the fourth quarter worth $1,711,000. Bank of Montreal Can raised its stake in Cempra by 187.8% in the first quarter. Bank of Montreal Can now owns 113,933 shares of the biotechnology company’s stock worth $428,000 after buying an additional 74,343 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in Cempra during the fourth quarter worth $560,000. Norges Bank acquired a new stake in Cempra during the fourth quarter worth $743,000. Finally, Bogle Investment Management L P DE raised its stake in Cempra by 607.0% in the first quarter. Bogle Investment Management L P DE now owns 709,518 shares of the biotechnology company’s stock worth $2,660,000 after buying an additional 609,168 shares during the last quarter. Institutional investors and hedge funds own 52.48% of the company’s stock.
Cempra (NASDAQ:CEMP) traded up 1.22% on Monday, hitting $4.15. 377,387 shares of the company’s stock traded hands. The stock’s market cap is $217.89 million. Cempra has a 12 month low of $2.55 and a 12 month high of $26.95. The stock has a 50 day moving average price of $4.25 and a 200-day moving average price of $3.80.
Cempra (NASDAQ:CEMP) last issued its quarterly earnings data on Friday, April 28th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.16. The business had revenue of $4.87 million for the quarter, compared to analysts’ expectations of $3.55 million. Cempra had a negative return on equity of 56.60% and a negative net margin of 551.45%. During the same period in the prior year, the firm earned ($0.61) EPS. Equities analysts predict that Cempra will post ($1.06) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/07/28/cempra-inc-nasdaqcemp-given-consensus-rating-of-hold-by-analysts-updated-updated-updated.html.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.